Aims & Scope
Concentrating on molecular biomarkers in cancer research, Cancer Biomarkers publishes original research findings (and reviews solicited by the editor) on the subject of the identification of markers associated with the disease processes whether or not they are an integral part of the pathological lesion. The disease markers may include, but are not limited to, genomic, epigenomic, proteomics, cellular and morphologic, and genetic factors predisposing to the disease or indicating the occurrence of the disease. Manuscripts on these factors or biomarkers, either in altered forms, abnormal concentrations or with abnormal tissue distribution leading to disease causation will be accepted.
Sudhir Srivastava, PhD, MPH
c/o IOS Press, Inc.
6751 Tepper Drive, Clifton
Fax: +1 703 830 2300
Karen S. Anderson, MD, PhD
Biodesign Institute, Arizona State University, Tempe, AZ
Surinder K. Batra, PhD
University of Nebraska Medical Center, Omaha, NE
Ajay Goel, PHD, AGAF
Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA
William E. Grizzle, MD, PhD
University of Alabama at Birmingham, Birmingham, AL
Sam Hanash, MD, PhD
University of Texas MD Anderson Cancer Center, Houston, TX
Kazufumi Honda, PhD
Nippon Medical School, Tokyo
Anna Lokshin, PhD
University of Pittsburgh Cancer Institute, Pittsburgh, PA
Attila T. Lorincz, PhD
Wolfson Institute of Preventive Medicine, Queen Mary University of London, London
Karin D. Rodland, PhD
Pacific Northwest National Laboratory, Richland, WA
Zhen Zhang, PhD
Johns Hopkins University School of Medicine, Baltimore, MD
Regional Associate Editors for China, Central China
Tony Hu, PhD
Arizona State University
Lei Wang, PhD
National Center for Human Genetic Resources
Heng Xie, MD, MPH, PhD
Shenzen Salubris Pharmaceuticals
Regional Associate Editors for China, East China
Liming Cheng, PhD
Tongji Medical College
Sidney W. Fu, MD, PhD
The George Washington University School of Medicine and Health Sciences
Regional Associate Editors for China, North China
Xiaohong Han, MD
Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs
YingYing Lu, MD, PhD
Comprehensive Liver Cancer Center
Regional Associate Editors for China, South China
Lei Zheng, MD, PhD
Southern Medical University, Guangzhou
Regional Associate Editors for China, West China
Li Jiang, MD, PhD
Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital
Ziding Feng, PhD
Fred Hutchinson Cancer Research Center, Seattle, WA
Steven J. Skates, PhD
Massachusetts General Hospital, Harvard Medical School, Boston, MA
Michael B. Atkins, MD
Georgetown University Medical Center
Timothy M. Block, PhD
Baruch S. Blumberg Institute
Roger Chammas, MD, PhD
University of São Paulo, Instituto do Câncer
Claudia Bessa P. Chaves, MD, PhD
Brazilian National Cancer Institute
David Chia, PhD
University of California
Arul M. Chinnaiyan, MD, PhD
University of Michigan
Miral Dizdaroglu, PhD
National Institute of Standards and Technology
Amit Gupta, MBBS MS, MBA
All India Institute of Medical Sciences
Michael Hollingsworth, PhD
University of Nebraska Medical Center
Ann M. Killary, PhD
University of Texas MD Anderson Cancer Center
Joshua LaBaer, PhD
Aija Linē, PhD
Latvian Biomedical Research and Study Centre
Alvin Y. Liu, PhD
University of Washington
Weizmann Institute of Science
Cesar Lopez-Camarillo, PhD
Universidad Autonoma de la Ciudad de Mexico
Bramanandam Manavathi, PhD
University of Hyderabad
Jeffrey R. Marks, PhD
Stephen J. Meltzer, MD
Johns Hopkins University
Patrick Nasarre, PhD
Medical University of South Carolina
Norbert Nass, PhD
Peng, Cheng, PhD
University of Queensland
Wenxin Qin, PhD
Shanghai Cancer Institute
William N. Rom, MD, MPH
Sol and Judith Bergstein Foundation
John Semmes, PhD
Eastern Virginia Medical School
David Sidransky, MD
Johns Hopkins University
Sanford Stass, MD
University of Maryland School of Medicine
Michael A. Tainsky, PhD
Wayne State University School of Medicine
Sebastien Taurin, PhD
Arabian Gulf University
Chemical Abstracts Service (CAS)
Microsoft Academic Search
Prous Science Integrity
Ulrich's Periodicals Directory
Web of Science: Biological Abstracts
Web of Science: BIOSIS Previews
Web of Science: Journal Citation Reports/Science Edition
Web of Science: Science Citation Index Expanded (SciSearch®)
By default, articles published in Cancer Biomarkers are available only to institutions and individuals with access rights. However, the journal offers all authors the option to purchase open access publication for their article as part of the IOS Press Open Library. This means that the final published version will be freely available to anyone worldwide, indefinitely, under a Creative Commons license and without the need to purchase access to the article. This is also referred to as “gold” open access.
Gold open access pricing
Authors who choose gold open access publication will be subject to an article publication charge of € 1250 / US$ 1450 for publication under the CC BY-NC 4.0 license or € 1850 / US$ 2080 for publication under the CC BY 4.0 license. Pricing is exclusive of possible taxes. After an article is accepted for publication, the corresponding author will be informed regarding the open access option during the production stages, and will have the opportunity to purchase open access for their article. It could be that the open access fee of an article is waived completely due an institutional agreement IOS Press has with the corresponding authors' institution. Please check the institutional agreements page for details.
Green open access
Authors who do not make use of the gold open access option may still make their article freely available using self-archiving, also referred to as green open access. Authors may make their final accepted manuscript available for free download from their personal or institutional website or institutional archive. This model is free for the author.
Peer Review Policy
Cancer Biomarkers is a peer-reviewed journal. Articles submitted to the journal undergo a single blind peer review process. This means that the identity of the authors is known to the reviewers but the identity of the reviewers is not communicated to the authors. Please visit our reviewer guidelines for further information about how to conduct a review.
All submitted manuscripts are subjected to initial appraisal by the Editor-in-Chief and, if found suitable for further consideration, to rigorous peer review by independent, anonymous expert referees. Reasons to reject a paper in the pre-screening process could for example be that the work does not fall within the aims and scope, the writing is of poor quality, the instructions to authors were not followed or the presented work is not novel.
Papers deemed suitable to be reviewed will be assigned to a handling editor. The handling editor will then invite reviewers to comment on the work. They might consider inviting the reviewers suggested by the author or not. Editors and reviewers are asked to excuse themselves from reviewing a submission if a conflict makes them unable to make an impartial scientific judgment or evaluation. Conflicts of interest include but are not limited to: collaboration with the authors in the past three years; any professional or financial affiliations that may be perceived as a conflict of interest; a history of personal differences with the author(s).
As a standard policy, decisions are based on three reviews, in some specific circumstances a minimum of two reviews may be deemed sufficient to make a decision on a paper. The Editor-in-Chief strives to ensure a typical turnaround time of 3 months.
Reviewers are asked to judge a paper on at least:
- Significance to field
- Relevance to journal
- Data analysis
- Literature review
- Writing style/clarity
Based on the received reviews the handling editor will propose to the Editor-in-Chief a recommendation:
- Minor revisions required
- Major revisions required
They mean the following:
- The manuscript is suitable for publication and only requires minor polishing; thus, no further reviews are requested.
- The authors are required to make moderate changes to their manuscript. The manuscript becomes acceptable for publication if the changes proposed by the reviewers and editors have been addressed satisfactorily. The revised manuscript will be examined by the Editor in Chief and possibly sent back to all (or a selection of) reviewers for a second round of reviews. Authors are requested to provide a letter to the reviewers detailing the improvements made for the resubmission.
- The manuscript cannot be accepted for publication in its current form. However, a major revision addressing all issues raised by the reviewers may be acceptable for publication. The revised manuscript will undergo a full second round of review. Authors are requested to provide a letter to the reviewers detailing the improvements made for the resubmission.
- The manuscript is rejected as it is deemed to be out of scope, not relevant, or not meeting the journal’s quality standards in terms of significance, novelty, and/or presentation.
Authors are notified by the Editor-in-Chief, whose decision is final.
Special Issue Announcement – The latest special issue has been published in Volume 33, Issue 4 (Apr 2022) on the topic "Collaboration Between US and Japan for the Early Detection of Cancer" (guest editor: Kazufumi Honda). All content is currently openly available until Oct 31, 2022. Read about it here!
Presentation at IOS Press Symposium – The journal's Editor-in-Chief Sudhir Srivastava was one of the esteemed scholars who participated in the IOS Press 35th anniversary symposium on Mar 31, 2022 in Amsterdam. The focus of his presentation was the journal's history, current developments, and prospects, as well as more broadly the area of biomarkers research. Discover more here!
Special Issue Announcement – Discover this special issue in Volume 33, Issue 2 (Feb 2022) on the topic "Applications of Artificial Intelligence in Biomarker Research" (guest editor: Karin Rodland, PhD). All content is currently openly available until Aug 31, 2022 and we are pleased to share more information here!
Journal Impact Factor – The latest Journal Citation Reports sees CBM's Impact Factor changing to 3.828 (Source Clarivate, 2022). The journal is listed in the Oncology category of Science Citation Index Expanded (SCIE).
Discover the contents of the latest journal issue:
Effect of D-mannose on Philadelphia chromosome-positive leukemia cells
Yuko Tanaka, Seiichi Okabe, Akihiko Gotoh
Comparison of CINtec PLUS cytology and cobas HPV test for triaging Canadian patients with LSIL cytology referred to colposcopy: A two-year prospective study
Sam Ratnam, Laura Gilbert, Dan Jang, Reza Alaghehbandan, Miranda Schell, Rob Needle, Anne Ecobichon-Morris, Arnav Wadhawan, Dustin Costescu, Laurie Elit, Peter Wang, George Zahariadis, Max Chernesky
Exosome-delivered circular RNA DLGAP4 induces chemoresistance via miR-143-HK2 axis in neuroblastoma
Li Yuan, Wei-Qiang Tan, Xiao-Yan Wu, Cheng-Guang He, Shai-Cheng Zhu, Ming Ye
Prognostic significance of a complement factor H autoantibody in early stage NSCLC
Michael J. Campa, Elizabeth B. Gottlin, Rikesh Gandhi, Ryan T. Bushey, James E. Herndon 2nd, Edward F. Patz Jr.